Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) (TAK)
Stock · NYSE · Health Care
$19.69as of 10/16/2026
Price chart
Active signals
Support level
$16.56
Industry
Biotechnology: Pharmaceutical Preparations
TAK Signal Track Record
How signals performed across all stocks →What TAK's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 28 | +2.1% | 75% | September 8, 2026 |
| Bollinger Band Breakdown | 26 | -0.3% | 50% | October 1, 2026 |
| 200-Day Moving Average TouchActive now | 24 | -1.2% | 46% | June 26, 2026 |
| Bollinger Band BreakoutActive now | 22 | +1.7% | 59% | September 17, 2026 |
| Any 20-session window (baseline) | -0.1% | 49% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About TAK
Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma-derived therapies, oncology, vaccines, and neuroscience. The company provides its products under the Entyvio, Gattex/Revestive, Takecab/Vocinti, EOHILIA, Takhzyro, Advate, Elaprase, Re…
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Employees
- 47,029
- Website
- www.takeda.com/jp
Fundamentals
- 1-day range
- $19.57$19.7
- Market cap
- $53.78B
- P/E (trailing)
- —
- P/E (forward)
- 37.07
- EPS (trailing)
- $-103.50
- Dividend yield
- 4.41%
- Beta
- 0.27
- Avg. volume
- 2.98M
- Ex-dividend date
- March 31, 2026
- Dividend pay date
- July 6, 2026
52-week range
$4,102$6,183
Next earnings: October 29, 2026confirmed
Forecasts
3 analyst ratings
Buy 67%
Hold 33%
Sell 0%
1-year price forecast
High
$25.15
+27.7%
Median
$22.09
+12.2%
Low
$21.06
+7.0%
Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) Competitors
Chosen by industry and closest market cap.
- TAKTakeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)$19.67▲ 1.13%Market cap $53.78BP/E —$4,102$6,183
- TEVATeva Pharmaceutical Industries Limited American Depositary Shares$41.5▲ 0.95%Market cap $40.56BP/E 68.57$6,207$12,990
- ONCBeOne Medicines Ltd. American Depositary Shares$369.06▼ 1.34%Market cap $36.67BP/E 61.27$205.51$319.24
- RPRXRoyalty Pharma plc Class A Ordinary Shares$60.96▲ 2.25%Market cap $32.97BP/E 41.57$35.23$64.38
- ZTSZoetis Inc. Class A Common Stock$79.38▲ 1.22%Market cap $32.39BP/E 12.43$68.77$148.3
- ALNYAlnylam Pharmaceuticals Inc. Common Stock$231.83▼ 0.94%Market cap $28.92BP/E 37.17$197.81$495.55
- INSMInsmed Incorporated Common Stock$96.27▼ 2.96%Market cap $28.73BP/E —$90.39$212.75
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| TAK Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) | $53.78B | — | $19.67 | ▲ 1.13% | $4,102$6,183 |
| TEVA Teva Pharmaceutical Industries Limited American Depositary Shares | $40.56B | 68.57 | $41.5 | ▲ 0.95% | $6,207$12,990 |
| ONC BeOne Medicines Ltd. American Depositary Shares | $36.67B | 61.27 | $369.06 | ▼ 1.34% | $205.51$319.24 |
| RPRX Royalty Pharma plc Class A Ordinary Shares | $32.97B | 41.57 | $60.96 | ▲ 2.25% | $35.23$64.38 |
| ZTS Zoetis Inc. Class A Common Stock | $32.39B | 12.43 | $79.38 | ▲ 1.22% | $68.77$148.3 |
| ALNY Alnylam Pharmaceuticals Inc. Common Stock | $28.92B | 37.17 | $231.83 | ▼ 0.94% | $197.81$495.55 |
| INSM Insmed Incorporated Common Stock | $28.73B | — | $96.27 | ▼ 2.96% | $90.39$212.75 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- Ascentage Pharma Stock Could More Than Double: Analystbenzinga · 10/16/2026
- eClinical Solutions Turns Clinical Data Intelligence Into Action at ENGAGE 2026Yahoo · 10/8/2026
- Asian Equities Traded in the US as American Depositary Receipts Tumble in Wednesday TradingYahoo · 10/7/2026
- Ironwood Pharmaceuticals: The Stock Is A Call On The Second Apraglutide Trial - BuySeekingAlpha · 10/7/2026
- Biopharma's Leapfrog Moment: The Launch of the Digital CMC ConsortiumYahoo · 10/6/2026
- Takeda (TSE:4502) Stock Looks Below Fair Value Even After A 120% RunYahoo · 10/1/2026
- Corus International Receives $6.4 Million Grant From Takeda to Reduce Climate-Related Health Risks in NepalYahoo · 10/1/2026
- Will Zasocitinib’s Phase 3 Outperformance Reshape Takeda Pharmaceutical's (TSE:4502) Immunology-Driven Pipeline NarrativeYahoo · 10/1/2026
- Takeda Pharmaceutical (TSE:4502) Could Be 13% Undervalued On Strong Phase 3 Psoriasis DataYahoo · 9/30/2026
Insider Activity
Insider Actions →Acquired
0
Disposed
446.5K
- Lauren Rusckowski Duprey · September 14, 2026 · Sale34.5K @ $18.54
- Andrew Stewart Plump · September 2, 2026 · Sale116.2K @ $18.49
- Andrew Stewart Plump · August 19, 2026 · Sale19.7K @ $18.49
- Nicola Deidre Petal Greenway · August 18, 2026 · Sale13.0K @ $18.11
- Elaine Mary Shannon · August 11, 2026 · Sale20.4K @ $17.55
- Julie So-Young Kim · August 10, 2026 · Sale89.1K @ $17.1
- Giles Richard Platford · August 10, 2026 · Sale31.1K @ $17.1
- Natalie Anne Marie Furney · August 10, 2026 · Sale30.9K @ $17.1
- Nicola Deidre Petal Greenway · August 10, 2026 · Sale33.6K @ $17.51
- Nicola Deidre Petal Greenway · August 10, 2026 · Sale975 @ $17.5
- Elaine Mary Shannon · August 10, 2026 · Sale4.0K @ $17.1
- Gabriele Ricci · August 10, 2026 · Sale25.1K @ $17.1
- Nicola Deidre Petal Greenway · August 10, 2026 · Sale6.8K @ $17.1
- Awny Samaan Botros Farajallah · August 10, 2026 · Sale14.0K @ $17.1
- Ramy Riad Ahmed Ibrahim · August 10, 2026 · Sale7.3K @ $17.1
Institutional Ownership
March 31, 2026
- Total shares held
- 99.47M
- Total value held
- $1.78B
- Institutional holders
- 357
Top holders this quarter
- Unknown19.10M
- Unknown7.12M
- Unknown6.47M
- Unknown6.42M
- Unknown5.62M
- Unknown4.43M
- Unknown3.18M
- Unknown3.12M
- Unknown2.99M
- Unknown2.74M
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
Takeda Launches Narcolepsy Drug in Asia, Presents PID Study Data
Takeda has launched its new narcolepsy treatment, ORZEYFUL, in Japan and China, marking the first availability of this orexin agonist for patients with narcolepsy type 1. The company also presented Phase 2/3 clinical data for its investigational drug TAK-881 for primary immunodeficiency disease at a recent medical conference. These pipeline advancements represent key milestones in Takeda's therapeutic portfolio expansion.
Takeda Launches Narcolepsy Drug in Asia, Presents PID Study Data. Takeda has launched its new narcolepsy treatment, ORZEYFUL, in Japan and China, marking the first availability of this orexin agonist for patients with narcolepsy type 1. The company also presented Phase 2/3 clinical data for its investigational drug TAK-881 for primary immunodeficiency disease at a recent medical conference. These pipeline advancements represent key milestones in Takeda's therapeutic portfolio expansion.